$NXTC
NextCure Inc

2024 Q1 Form 10-K Financial Statement

#000155837024003672 Filed on March 21, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.364M $3.963M $19.71M
YoY Change -19.54% -19.92% -9.23%
% of Gross Profit
Research & Development $11.40M $11.83M $47.93M
YoY Change -2.14% -7.76% -11.56%
% of Gross Profit
Depreciation & Amortization $790.0K $824.0K $3.700M
YoY Change -17.71% -18.17% -9.76%
% of Gross Profit
Operating Expenses $18.30M $15.79M $67.64M
YoY Change 7.22% -11.15% -10.9%
Operating Profit -$18.30M -$67.64M
YoY Change 7.22% -10.9%
Interest Expense $1.197M $1.323M $4.914M
YoY Change 22.77% 180.89% 317.86%
% of Operating Profit
Other Income/Expense, Net $1.197M $1.323M $4.914M
YoY Change 22.77% 317.86%
Pretax Income -$17.11M -$14.47M -$62.72M
YoY Change 6.28% -16.38% -16.07%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$17.11M -$14.47M -$62.72M
YoY Change 6.28% -16.38% -16.07%
Net Earnings / Revenue
Basic Earnings Per Share -$0.61 -$2.25
Diluted Earnings Per Share -$0.61 -$0.52 -$2.25
COMMON SHARES
Basic Shares Outstanding 27.90M 27.90M 27.84M
Diluted Shares Outstanding 27.90M 27.84M

Balance Sheet

Concept 2024 Q1 2023 Q4 2023
SHORT-TERM ASSETS
Cash & Short-Term Investments $96.00M $108.3M $108.3M
YoY Change -34.02% -32.28% -32.28%
Cash & Equivalents $18.36M $13.08M $13.08M
Short-Term Investments $77.64M $95.22M $95.22M
Other Short-Term Assets $6.551M $4.426M $4.426M
YoY Change 91.27% 8.69% 8.69%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $102.6M $112.7M $112.7M
YoY Change -31.14% -31.26% -31.26%
LONG-TERM ASSETS
Property, Plant & Equipment $7.097M $9.033M $13.43M
YoY Change -36.55% -24.07% -20.59%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.878M $1.882M $1.882M
YoY Change -33.48% -42.36% -42.36%
Total Long-Term Assets $12.61M $15.31M $15.31M
YoY Change -33.2% -24.11% -24.11%
TOTAL ASSETS
Total Short-Term Assets $102.6M $112.7M $112.7M
Total Long-Term Assets $12.61M $15.31M $15.31M
Total Assets $115.2M $128.0M $128.0M
YoY Change -31.37% -30.47% -30.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.491M $2.330M $2.330M
YoY Change 134.03% -45.43% -45.43%
Accrued Expenses $5.092M $4.553M $4.553M
YoY Change 17.14% -6.26% -6.26%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.583M $6.883M $6.883M
YoY Change 52.94% -24.59% -24.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $755.0K $785.0K $6.734M
YoY Change -13.42% -12.68% -10.26%
Total Long-Term Liabilities $755.0K $785.0K $6.734M
YoY Change -13.42% -12.68% -10.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.583M $6.883M $6.883M
Total Long-Term Liabilities $755.0K $785.0K $6.734M
Total Liabilities $16.11M $13.62M $13.62M
YoY Change 18.57% -18.12% -18.12%
SHAREHOLDERS EQUITY
Retained Earnings -$341.6M -$324.5M
YoY Change 22.94% 23.96%
Common Stock $28.00K $28.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $99.05M $114.4M $114.4M
YoY Change
Total Liabilities & Shareholders Equity $115.2M $128.0M $128.0M
YoY Change -31.37% -30.47% -30.47%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023
OPERATING ACTIVITIES
Net Income -$17.11M -$14.47M -$62.72M
YoY Change 6.28% -16.38% -16.07%
Depreciation, Depletion And Amortization $790.0K $824.0K $3.700M
YoY Change -17.71% -18.17% -9.76%
Cash From Operating Activities -$12.61M -$10.67M -$52.97M
YoY Change -14.7% 19.23% -1.69%
INVESTING ACTIVITIES
Capital Expenditures $37.00K $13.00K $820.0K
YoY Change -85.08% -98.5% -61.25%
Acquisitions
YoY Change
Other Investing Activities $17.92M $4.175M $40.09M
YoY Change -2.46% -21.71% -42.8%
Cash From Investing Activities $17.88M $4.162M $39.27M
YoY Change -1.33% -6.85% -42.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000K 71.00K 154.0K
YoY Change 16.39% -23.0%
NET CHANGE
Cash From Operating Activities -12.61M -10.67M -52.97M
Cash From Investing Activities 17.88M 4.162M 39.27M
Cash From Financing Activities 1.000K 71.00K 154.0K
Net Change In Cash 5.276M -6.437M -13.55M
YoY Change 57.82% 45.63% -194.79%
FREE CASH FLOW
Cash From Operating Activities -$12.61M -$10.67M -$52.97M
Capital Expenditures $37.00K $13.00K $820.0K
Free Cash Flow -$12.64M -$10.68M -$53.79M
YoY Change -15.86% 8.85% -3.94%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.25
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.69
CY2023 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27836584
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27744209
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.nextcure.com/20231231#AccruedAndOtherLiabilitiesCurrent
CY2023Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.nextcure.com/20231231#AccruedAndOtherLiabilitiesCurrent
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27903027
CY2023 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023 dei Entity Central Index Key
EntityCentralIndexKey
0001661059
CY2023 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2023 dei Amendment Flag
AmendmentFlag
false
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27774536
CY2022Q4 nxtc Fair Values Assets Level1 To Level2 Transfers Amount
FairValuesAssetsLevel1ToLevel2TransfersAmount
0
CY2023Q4 nxtc Fair Values Assets Level1 To Level2 Transfers Amount
FairValuesAssetsLevel1ToLevel2TransfersAmount
0
CY2022Q4 nxtc Fair Values Assets Level2 To Level1 Transfers Amount
FairValuesAssetsLevel2ToLevel1TransfersAmount
0
CY2023Q4 nxtc Fair Values Assets Level2 To Level1 Transfers Amount
FairValuesAssetsLevel2ToLevel1TransfersAmount
0
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27903027
CY2019Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1245
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023 dei Document Type
DocumentType
10-K
CY2023 dei Document Annual Report
DocumentAnnualReport
true
CY2023 dei Document Period End Date
DocumentPeriodEndDate
2023-12-31
CY2023 dei Document Transition Report
DocumentTransitionReport
false
CY2023 dei Entity File Number
EntityFileNumber
001-38905
CY2023 dei Entity Registrant Name
EntityRegistrantName
NextCure, Inc.
CY2023 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-5231247
CY2023 dei Entity Address Address Line1
EntityAddressAddressLine1
9000 Virginia Manor Road, Suite 200
CY2023 dei Entity Address City Or Town
EntityAddressCityOrTown
Beltsville
CY2023 dei Entity Address State Or Province
EntityAddressStateOrProvince
MD
CY2023 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
20705
CY2023 dei City Area Code
CityAreaCode
240
CY2023 dei Local Phone Number
LocalPhoneNumber
399-4900
CY2023 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
CY2023 dei Trading Symbol
TradingSymbol
NXTC
CY2023 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2023 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2023 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023 dei Entity Small Business
EntitySmallBusiness
true
CY2023 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2023 dei Document Fin Stmt Error Correction Flag
DocumentFinStmtErrorCorrectionFlag
false
CY2023 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Public Float
EntityPublicFloat
49200000
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27903027
CY2023 dei Auditor Firm
AuditorFirmId
42
CY2023 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2023 dei Auditor Location
AuditorLocation
Baltimore, MD
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13082000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26630000
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
95217000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
133281000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4426000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4072000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
112725000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
163983000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9033000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11897000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4398000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5016000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1882000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3265000
CY2023Q4 us-gaap Assets
Assets
128038000
CY2022Q4 us-gaap Assets
Assets
184161000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2330000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4270000
CY2023Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4553000
CY2022Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4857000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6883000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9127000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5949000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6605000
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
785000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
899000
CY2023Q4 us-gaap Liabilities
Liabilities
13617000
CY2022Q4 us-gaap Liabilities
Liabilities
16631000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27903027
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27774536
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
28000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
439097000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
430755000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-222000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1494000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-324482000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-261759000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
114421000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
167530000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
128038000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184161000
CY2023 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
47931000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54199000
CY2023 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
19706000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
21710000
CY2023 us-gaap Operating Expenses
OperatingExpenses
67637000
CY2022 us-gaap Operating Expenses
OperatingExpenses
75909000
CY2023 us-gaap Operating Income Loss
OperatingIncomeLoss
-67637000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-75909000
CY2023 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4914000
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1176000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-62723000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-74733000
CY2023 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.25
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.69
CY2023 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27836584
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27744209
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-62723000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-74733000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
1272000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-831000
CY2023 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-61451000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-75564000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
233386000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9508000
CY2022 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
66000
CY2022 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
134000
CY2022 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2022 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
-831000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-74733000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
167530000
CY2023 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8188000
CY2023 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2023 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
149000
CY2023 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
0
CY2023 nxtc Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
1272000
CY2023 us-gaap Net Income Loss
NetIncomeLoss
-62723000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
114421000
CY2023 us-gaap Profit Loss
ProfitLoss
-62723000
CY2022 us-gaap Profit Loss
ProfitLoss
-74733000
CY2023 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
3684000
CY2022 nxtc Depreciation Depletion And Amortization And Other
DepreciationDepletionAndAmortizationAndOther
4124000
CY2023 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
756000
CY2022 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-3047000
CY2023 us-gaap Share Based Compensation
ShareBasedCompensation
8188000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
9508000
CY2023 nxtc Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
573000
CY2022 nxtc Noncash Operating Lease Expense
NoncashOperatingLeaseExpense
356000
CY2022 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-87000
CY2023 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1074000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2038000
CY2023 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1940000
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2328000
CY2023 nxtc Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
304000
CY2022 nxtc Increase Decrease In Accrued And Other Current Liabilities
IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
641000
CY2023 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-656000
CY2023 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-114000
CY2023 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-52974000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-53886000
CY2023 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
113597000
CY2022 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
104739000
CY2023 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
73505000
CY2022 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34644000
CY2023 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
820000
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2116000
CY2023 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
39272000
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
67979000
CY2023 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
CY2022 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
66000
CY2023 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
149000
CY2022 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
134000
CY2023 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
154000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
200000
CY2023 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13548000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
14293000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26630000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12337000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13082000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26630000
CY2023 us-gaap Interest Paid Net
InterestPaidNet
81000
CY2022 us-gaap Interest Paid Net
InterestPaidNet
90000
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6047000
CY2022 nxtc Operating Lease Liabilities Initial Lease Recognition Amount
OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount
7549000
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15560569
CY2019Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2019Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4077192
CY2019Q4 us-gaap Share Price
SharePrice
36.75
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
611578
CY2019Q4 us-gaap Share Price
SharePrice
36.75
CY2019Q4 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
160900000
CY2019Q4 nxtc Payments Of Underwriting Discounts And Commissions
PaymentsOfUnderwritingDiscountsAndCommissions
10300000
CY2019Q4 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1000000.0
CY2023 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p>
CY2023 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at two accredited financial institutions that are federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions and corporate bonds with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p>
CY2023 nxtc Number Of Accredited Financial Institutions That Are Federally Insured
NumberOfAccreditedFinancialInstitutionsThatAreFederallyInsured
2
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
41000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
263000
CY2023Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
95217000
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
134775000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1494000
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest
DebtSecuritiesAvailableForSaleExcludingAccruedInterest
133281000
CY2023 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
0
CY2022 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2023 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022 us-gaap Debt Securities Available For Sale Realized Gain
DebtSecuritiesAvailableForSaleRealizedGain
9000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
80300000
CY2023Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
7500000
CY2023 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest Before Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
95439000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
92512000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
92268000
CY2023Q4 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
2927000
CY2023Q4 nxtc Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
2949000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date Amortized Cost Basis
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
95439000
CY2023Q4 us-gaap Available For Sale Securities Debt Maturities Single Maturity Date
AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
95217000
CY2023 nxtc Interest Income Non Operating
InterestIncomeNonOperating
800000
CY2022 nxtc Interest Income Non Operating
InterestIncomeNonOperating
700000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
29262000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
28527000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20229000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16630000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9033000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11897000
CY2023 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3700000
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4100000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
992000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1639000
CY2023Q4 nxtc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1133000
CY2022Q4 nxtc Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
1531000
CY2023Q4 nxtc Accrued Sponsored Research Expense Current
AccruedSponsoredResearchExpenseCurrent
424000
CY2022Q4 nxtc Accrued Sponsored Research Expense Current
AccruedSponsoredResearchExpenseCurrent
417000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
656000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
518000
CY2023Q4 nxtc Accrued Operating Expenses Current
AccruedOperatingExpensesCurrent
1235000
CY2022Q4 nxtc Accrued Operating Expenses Current
AccruedOperatingExpensesCurrent
647000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
113000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
105000
CY2023Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4553000
CY2022Q4 nxtc Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
4857000
CY2023Q4 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2023 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2023 us-gaap Operating Lease Expense
OperatingLeaseExpense
1100000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000.0
CY2023 us-gaap Operating Lease Payments
OperatingLeasePayments
1000000.0
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
900000
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y3M
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0747
CY2023 nxtc Number Of Votes Per Share
NumberOfVotesPerShare
1
CY2023 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8200000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9500000
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
7700000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1127000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1214000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1355000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1396000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1438000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1857000
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
8387000
CY2023Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1782000
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
6605000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27903027
CY2023 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2023 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8188000
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9508000
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.814
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
203900000
CY2023 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6817102
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5262179
CY2023 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2023 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.067
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.065
CY2023 nxtc Effective Income Tax Rate Reconciliation Tax Credits Research Net
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchNet
0.045
CY2022 nxtc Effective Income Tax Rate Reconciliation Tax Credits Research Net
EffectiveIncomeTaxRateReconciliationTaxCreditsResearchNet
0.034
CY2023 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.009
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.017
CY2023 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.001
CY2022 us-gaap Effective Income Tax Rate Reconciliation Prior Year Income Taxes
EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
-0.001
CY2023 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.312
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.291
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56409000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
49789000
CY2023Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
14208000
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
11395000
CY2023Q4 nxtc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
20776000
CY2022Q4 nxtc Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
12424000
CY2023Q4 nxtc Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1818000
CY2022Q4 nxtc Deferred Tax Assets Operating Lease Liabilities
DeferredTaxAssetsOperatingLeaseLiabilities
1960000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
6053000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4389000
CY2023Q4 nxtc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
1076000
CY2022Q4 nxtc Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
1305000
CY2023Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
100340000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
81262000
CY2023Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
98960000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79724000
CY2023Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1380000
CY2022Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1538000
CY2023Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1380000
CY2022Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
1538000
CY2023Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1380000
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1538000
CY2023 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
19200000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
208500000
CY2023Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
181100000
CY2023Q4 nxtc Deferred Tax Assets Tax Credit Carryforwards Research And Development Federal
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal
14100000
CY2023Q4 nxtc Deferred Tax Assets Tax Credit Carryforwards Research And Development State
DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState
100000
CY2023Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
400000
CY2022 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
300000
CY2023Q4 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q4 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001558370-24-003672-index-headers.html Edgar Link pending
0001558370-24-003672-index.html Edgar Link pending
0001558370-24-003672.txt Edgar Link pending
0001558370-24-003672-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nxtc-20231231.xsd Edgar Link pending
nxtc-20231231x10k.htm Edgar Link pending
nxtc-20231231x10k005.jpg Edgar Link pending
nxtc-20231231x10k006.jpg Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nxtc-20231231x10k_htm.xml Edgar Link completed
nxtc-20231231xex10d30.htm Edgar Link pending
nxtc-20231231xex23d1.htm Edgar Link pending
nxtc-20231231xex31d1.htm Edgar Link pending
nxtc-20231231xex31d2.htm Edgar Link pending
nxtc-20231231xex32d1.htm Edgar Link pending
nxtc-20231231xex97.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
nxtc-20231231_def.xml Edgar Link unprocessable
nxtc-20231231_pre.xml Edgar Link unprocessable
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nxtc-20231231_cal.xml Edgar Link unprocessable
nxtc-20231231_lab.xml Edgar Link unprocessable